Site icon Market Globalist

Keep an eye on why Veru Inc. (NASDAQ: VERU) are shares soaring above limits in the premarket?

BIGC Stock

BIGC Stock

Veru Inc. (NASDAQ: VERU), the stock jumped 21.79% to $7.74 in the premarket session after a biopharmaceutical oncology corporation focused on the production of new cancer treatment drugs, today reported high net sales and gross profit for its fourth quarter and full-year ended September 30, 2020, for fiscal 2020.

4th-quarter: YOY highlights

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

From $8.7 million, net sales rose 35% to $11.7 million years over year.

FC2 net prescription revenue increased 87% from $4.7 million to $8.7 million.

The company’s Gross profit soared 64% from $5.8 million to $9.6 million. It’s Gross margin rose from 67% of net revenue to 81% of net revenue.

The net loss was $11.3 million, with a non-cash impairment fee of $14.1 million relating to intangible assets. Net revenue was $2.8 million with an operating deficit of $1.5 million, minus the non-cash impairment fee.

Before the fee for non-cash impairment, the net loss was $11.8 million, or $0.17 per share, compared to $3.1 million, or $0.05 per share.

Full-year: YOY Highlights

From $31.8 million, net sales grew 34% to $42.6 million.

 Company sales of prescription FC2 soared 93% from $14.1 million to $27.1 million. Its Gross profit gained 42% from $21.7 million to $30.8 million.

Gross margin rose from 68% of net sales to 72% of net revenue.

The net loss was $14.7 million, with a non-cash impairment fee of $14.1 million relating to intangible assets. 

Compared to $12.0 million, or $0.19 per share, the net loss, which contains the non-cash impairment fee, was $19.0 million, or $0.28 per share.